A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer

Conclusions The MTD of OSI-906 and everolimus was 50 mg BID and 5 mg QD, respectively. No indications of clinical activity were observed in refractory mCRC patients.

http://link.springer.com/10.1007/s10637-014-0177-3

Source: Investigational New Drugs - October 22, 2014 Category: Drugs & Pharmacology Source Type: research